Effects of neoadjuvant androgen deprivation therapy on prostatic cancer

被引:0
|
作者
Polito, M
Muzzonigro, G
Minardi, D
Montironi, R
机构
[1] UNIV ANCONA, SCH MED, INST UROL, ANCONA, ITALY
[2] UNIV ANCONA, SCH MED, INST PATHOL ANAT & HISTOPATHOL, ANCONA, ITALY
关键词
prostatic cancer; neoadjuvant androgen deprivation therapy;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In this study, we analyzed the involutive effects of androgen deprivation therapy on normal and neoplastic prostatic tissue, to investigate whether androgen deprivation prior to radical prostatectomy could reduce the incidence of extracapsular extension, positive margins, positive seminal vesicles, and positive lymph nodes in patients with prostatic carcinoma. Methods: We performed neoadjuvant androgen deprivation therapy (NADT) in 41 patients cT2N0M0 and in 21 patients cT3N0M0. Criteria to evaluate the effectiveness of NADT included prostate volume, tumor volume, serum prostate-specific antigen (PSA), staging, grading, histological modifications of the tumor, and evaluation of indices of cellular proliferation. Results: We observed a decrease in prostate and tumor volume, as well as serum PSA a down-staging effect was observed in 14.51% of cases. Evaluation of proliferating-cell nuclear antigen (PCNA) revealed a decrease of proliferative activity in treated prostatic carcinoma. The histological modifications after neoadjuvant therapy consisted of cellular necrosis with apoptotic phenomena, dense chromatin without nucleoli, absence of mitosis, inflammatory infiltrate, and interstitial fibrosis. Regressive aspects similar to those of neoplastic cells were observed in prostatic intraepithelial neoplasia. Conclusion: Our assessment of the biologic effects of NADT on tumoral activity of prostatic carcinoma led us to conclude that NADT can reduce the cellular proliferation of neoplastic cells.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [31] Androgen deprivation therapy for prostate cancer
    Singer, Eric A.
    Golijanin, Dragan J.
    Miyamoto, Hiroshi
    Messing, Edward M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (02) : 211 - 228
  • [32] Histologic basis and optimal duration for neoadjuvant androgen deprivation therapy
    Civantos, F
    Pinto, JE
    Soloway, MS
    MOLECULAR UROLOGY, 1998, 2 (03) : 95 - 100
  • [33] The effects of androgen deprivation therapy on the 18f-choline uptake in prostate cancer patients undergoing neoadjuvant treatment
    Evangelista, Laura
    Zattoni, Fabio
    Guttilla, Andrea
    Saladini, Giorgio
    Zattoni, Filiberto
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [34] Metabolic effects of androgen deprivation therapy
    Choi, See Min
    Kam, Sung Chul
    KOREAN JOURNAL OF UROLOGY, 2015, 56 (01) : 12 - 18
  • [35] Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy
    Yoshifumi Kadono
    Takahiro Nohara
    Satoru Ueno
    Kouji Izumi
    Yasuhide Kitagawa
    Hiroyuki Konaka
    Atsushi Mizokami
    Mizuki Onozawa
    Shiro Hinotsu
    Hideyuki Akaza
    Mikio Namiki
    World Journal of Urology, 2016, 34 : 261 - 267
  • [36] The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
    Fair, WR
    Cookson, MS
    Stroumbakis, N
    Cohen, D
    Aprikian, AG
    Wang, Y
    Russo, P
    Soloway, SM
    Sogani, P
    Sheinfeld, J
    Herr, H
    Dalgabni, G
    Begg, CB
    Heston, WDW
    Reuter, VE
    UROLOGY, 1997, 49 (3A) : 46 - 55
  • [37] Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy
    Kadono, Yoshifumi
    Nohara, Takahiro
    Ueno, Satoru
    Izumi, Kouji
    Kitagawa, Yasuhide
    Konaka, Hiroyuki
    Mizokami, Atsushi
    Onozawa, Mizuki
    Hinotsu, Shiro
    Akaza, Hideyuki
    Namiki, Mikio
    WORLD JOURNAL OF UROLOGY, 2016, 34 (02) : 261 - 267
  • [38] VALIDATION OF TNM CLASSIFICATION FOR METASTATIC PROSTATIC CANCER TREATED USING PRIMARY ANDROGEN DEPRIVATION THERAPY
    Kadono, Yoshifumi
    Nohara, Takahiro
    Ueno, Satoru
    Izumi, Kouji
    Kitagawa, Yasuhide
    Konaka, Hiroyuki
    Mizokami, Atsushi
    Onozawa, Mizuki
    Hinotsu, Shiro
    Akaza, Hideyuki
    Namiki, Mikio
    JOURNAL OF UROLOGY, 2016, 195 (04): : E316 - E316
  • [39] TREATMENT OF PROSTATIC-CANCER - NEWER FORMS OF ANDROGEN DEPRIVATION
    SOLOWAY, MS
    POSTGRADUATE MEDICINE, 1986, 80 (01) : 249 - &
  • [40] Adjuvant versus neoadjuvant androgen deprivation with radiation therapy for prostate cancer: Does sequencing matter?
    Weller, Michael A.
    Tendulkar, Rahul D.
    Reddy, Chandana A.
    Stephans, Kevin L.
    Kupelian, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)